Gland Pharma shares surged after strong Q1 results and positive commentary from brokerages citing a turnaround at its European unit Cenexi. EBITDA margins expanded to 24.4%, and net profit rose 50% YoY. Despite weak U.S. sales, growth in Europe and new launches supported the outlook. Brokerages raised earnings estimates and targets, expecting further gains as Cenexi scales profitability.
BlackRock expands AI push with new robotics ETF as investor enthusiasm cools
BlackRock has launched a new robotics focused ETF as investors become more selective about AI investments. The fund targets companies using intelligent machines across industries
October 21, 2026